Clinical Edge Journal Scan

Meta-analysis shows association between diabetes and different BC subtypes in postmenopausal women


 

Key clinical point: Women, particularly post-menopausal women, with diabetes mellitus (DM) faced a higher risk of developing different subtypes of breast cancer (BC).

Major finding: Women with DM had a 20% greater risk of developing BC (risk ratio [RR] 1.20; 95% CI 1.11-1.29), with the risk persisting only in postmenopausal women (RR 1.12; 95% CI 1.07-1.17). The risk of estrogen receptor-negative BC (RR 1.16; 95% CI 1.04-1.30) and triple-negative BC (RR 1.41; 95% CI 1.01-1.96) subtypes increased in patients with DM.

Study details: This meta-analysis of 70 cohort and case-control studies included premenopausal and postmenopausal women with or without DM who developed BC.

Disclosures: JM Chan received funding from the Cancer League Foundation. RE Graff, the corresponding author, declared being supported by a Young Investigator Award from the Prostate Cancer Foundation.

Source: Xiong F et al. Diabetes and incidence of breast cancer and its molecular subtypes: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2023;e3709 (Aug 7). doi: 10.1002/dmrr.3709

Recommended Reading

Older women risk overdiagnosis with mammograms: Study
MDedge Hematology and Oncology
Alcohol consumption may not influence breast cancer prognosis, study
MDedge Hematology and Oncology
Higher chances of BC overdiagnosis among older women
MDedge Hematology and Oncology
Breast cancer diagnosis and treatment may accelerate biological aging
MDedge Hematology and Oncology
Metronomic oral vinorelbine, cyclophosphamide, and capecitabine may be a chemotherapy option in ER+/ERBB2− advanced BC
MDedge Hematology and Oncology
Axillary lymph node dissection omission does not affect systemic therapy recommendations in cN+ BC
MDedge Hematology and Oncology
Elevated plasma apolipoprotein M level associated with reduced mortality in ER+/HER2− metastatic BC
MDedge Hematology and Oncology
T1-2N0 ER− BC: Most, if not all, elderly women benefit from adjuvant radiotherapy
MDedge Hematology and Oncology
ER+/HER2+ BC: Fulvestrant shows promise both with and without anti-HER2 therapy
MDedge Hematology and Oncology
Metformin may protect against paclitaxel-induced peripheral neuropathy in BC
MDedge Hematology and Oncology